The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice
Open accessAbstract
Cancer immunotherapeutic approaches induce tumor-specific immune responses, in particular CTL responses, in many patients treated. However, such approaches are clinically beneficial to only a few patients. We set out to investigate one possible explanation for the failure of CTLs to eliminate tumors, specifically, the concept that this failure is not dependent on inhibition of T cell function. In a previous study, we found that in mice, myeloid-derived suppressor cells (MDSCs) are a source of the free radical peroxynitrite (PNT). Here, we show that pre-treatment of mouse and human tumor cells with PNT or with MDSCs inhibits binding of processed peptides to tumor cell-associated MHC, and as a result, tumor cells become resistant to antigen-specific CTLs. This effect was abrogated in MDSCs treated with a PNT inhibitor. In a mouse model of tumor-associated inflammation in which the antitumor effects of antigen-specific CTLs are eradicated by expression of IL-1β in the tumor cells, we determined that therapeutic failure was not caused by more profound suppression of CTLs by IL-1β-expressing tumors than tumors not expressing this proinflammatory cytokine. Rather, therapeutic failure was a result of the presence of PNT. Clinical relevance for these data was suggested by the observation that myeloid cells were the predominant source of PNT in human lung, pancreatic, and breast cancer samples. Our data therefore suggest what we believe to be a novel mechanism of MDSC-mediated tumor cell resistance to CTLs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Self-citationNitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
Nagaraj, S., Gupta, K., Pisarev, V., Kinarsky, L., Sherman, S., Kang, L., Herber, D. L., Schneck, J., & Gabrilovich, D. I. (2007) · Nature Medicine · doi:10.1038/nm1609 · Cited by 1,174
Self-citationCorzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173
Self-citationOverwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth-Dreese, F. A., Dellemijn, T. A., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 925
Schmielau, J., & Finn, O. J. (2001) · PubMed · Cited by 867
Kusmartsev, S., Nefedova, Y., Yoder, D., & Gabrilovich, D. I. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.989 · Cited by 850
Self-citationMechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells
Corzo, C. A., Cotter, M. J., Cheng, P., Cheng, F., Kusmartsev, S., Sotomayor, E., Padhya, T., McCaffrey, T. V., McCaffrey, J. C., & Gabrilovich, D. I. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900092 · Cited by 763
Self-citationPorgador, A., Yewdell, J. W., Deng, Y., Bennink, J. R., & Germain, R. N. (1997) · Immunity · doi:10.1016/s1074-7613(00)80447-1 · Cited by 669
Doedens, A. L., Stockmann, C., Rubinstein, M. P., Liao, D., Zhang, N., DeNardo, D. G., Coussens, L. M., Karin, M., Goldrath, A. W., & Johnson, R. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1439 · Cited by 652
Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer
Liby, K. T., Yore, M. M., & Sporn, M. B. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2129 · Cited by 637
Self-citationAdoptive cell therapy for the treatment of patients with metastatic melanoma
Rosenberg, S. A., & Dudley, M. E. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.002 · Cited by 595
Dinkova-Kostova, A. T., Liby, K. T., Stephenson, K. K., Holtzclaw, W. D., Gao, X., Suh, N., Williams, C., Risingsong, R., Honda, T., Gribble, G. W., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500815102 · Cited by 569
Self-citationPeroxynitrite reactivity with amino acids and proteins
Alvarez, B., & Radi, R. (2003) · Amino Acids · doi:10.1007/s00726-003-0018-8 · Cited by 560
Inflammation Induces Myeloid-Derived Suppressor Cells that Facilitate Tumor Progression
Bunt, S. K., Sinha, P., Clements, V. K., Leips, J., & Ostrand-Rosenberg, S. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.284 · Cited by 539
Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin
Lechner, M., Lirk, P., & Rieder, J. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.04.004 · Cited by 410
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers
Bronte, V., Kasic, T., Gri, G., Gallana, K., Borsellino, G., Marigo, I., Battistini, L., Iafrate, M., Prayer-Galetti, T., Pagano, F., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042028 · Cited by 396
Kono, K., Salazar‐Onfray, F., Petersson, M., Hansson, J., Masucci, G., Wasserman, K., Nakazawa, T., Anderson, P., & Kiessling, R. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260620 · Cited by 359
Otsuji, M., Kimura, Y., Aoe, T., Okamoto, Y., & Saito, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.23.13119 · Cited by 338
Tumor-Associated CD8+ T Cell Tolerance Induced by Bone Marrow-Derived Immature Myeloid Cells
Kusmartsev, S., Nagaraj, S., & Gabrilovich, D. I. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4583 · Cited by 310
Self-citationT cell homeostatic proliferation elicits effective antitumor autoimmunity
Dummer, W., Niethammer, A. G., Baccalà, R., Lawson, B. R., Wagner, N., Reisfeld, R. A., & Theofilopoulos, A. N. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15175 · Cited by 308
Nagaraj, S., Youn, J.-I., Weber, H., Iclozan, C., Lu, L., Cotter, M. J., Meyer, C., Becerra, C. R., Fishman, M., Antonia, S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3272 · Cited by 286
Self-citationWrzesinski, C., Paulos, C. M., Kaiser, A., Muranski, P., Palmer, D. C., Gattinoni, L., Yu, Z., Rosenberg, S. A., & Restifo, N. P. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181b88ffc · Cited by 283
T cell homeostatic proliferation elicits effective antitumor autoimmunity
Dummer, W., Niethammer, A. G., Baccala, R., Lawson, B. R., Wagner, N., Reisfeld, R. A., & Theofilopoulos, A. N. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215175 · Cited by 270
Is interleukin‐1 a good or bad ‘guy’ in tumor immunobiology and immunotherapy?
Apte, R. N., & Voronov, E. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00615.x · Cited by 239
Adoptive immunotherapy of cancer using CD4+ T cells
Muranski, P., & Restifo, N. P. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.02.004 · Cited by 220
Honda, T., Rounds, B. V., Gribble, G. W., Suh, N., Wang, Y., & Sporn, M. B. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00479-x · Cited by 204
Self-citationVakkala, M. A., Kahlos, K., Lakari, E., Pääkkö, P. K., Kinnula, V. L., & Soini, Y. (2000) · PubMed · Cited by 196
Yates, M. S., Kwak, M.-K., Egner, P. A., Groopman, J. D., Bodreddigari, S., Sutter, T. R., Baumgartner, K. J., Roebuck, B. D., Liby, K. T., Yore, M. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3823 · Cited by 191
Self-citationActivated macrophages induce structural abnormalities of the T cell receptor-CD3 complex.
Aoe, T., Okamoto, Y., & Saito, T. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.181.5.1881 · Cited by 145
Cobbs, C., Whisenhunt, T. R., Wesemann, D. R., Harkins, L. E., Meir, E. G. V., & Samanta, M. (2003) · PubMed · Cited by 144
Tumor iNOS predicts poor survival for stage III melanoma patients
Ekmekçioglu, S., Ellerhorst, J. A., Prieto, V. G., Johnson, M. M., Broemeling, L. D., & Grimm, E. A. (2006) · International Journal of Cancer · doi:10.1002/ijc.21767 · Cited by 135
Toll-like Receptors in Tumor Immunotherapy
Paulos, C. M., Kaiser, A., Wrzesinski, C., Hinrichs, C. S., Cassard, L., Boni, A., Muranski, P. J., Sanchez-Perez, L. A., Palmer, D. C., Yu, Z., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1378 · Cited by 134
Nakamura, Y., Yasuoka, H., Tsujimoto, M., Yoshidome, K., Nakahara, M., Nakao, K., Nakamura, M., & Kakudo, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1269 · Cited by 133
Abnormalities in nitric oxide and its derivatives in lung cancer
Masri, F. A., Comhair, S. A. A., Koeck, T., Xu, W., Janocha, A., Ghosh, S., Dweik, R. A., Golish, J., Kinter, M., Stuehr, D. J., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200411-1523oc · Cited by 128
Oxidative stress in phagocytes—“The enemy within”
Splettstoesser, W. D., & Schuff‐Werner, P. (2002) · Microscopy Research and Technique · doi:10.1002/jemt.10098 · Cited by 125
Nitric oxide synthase expression and nitric oxide production in human colon carcinoma tissue
Kojima, M., Morisaki, T., Tsukahara, Y., Uchiyama, A., Matsunari, Y., Mibu, R., & Tanaka, M. (1999) · Journal of Surgical Oncology · doi:10.1002/(sici)1096-9098(199904)70:4<222::aid-jso5>3.0.co;2-g · Cited by 122
Vickers, S. M., MacMillan-Crow, L. A., Green, M., Ellis, C. M., & Thompson, J. C. (1999) · Archives of Surgery · doi:10.1001/archsurg.134.3.245 · Cited by 113
Birnboim, H. C., Lemay, A., Lam, D. K. Y., Goldstein, R., & Webb, J. R. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.2.528 · Cited by 109
Full-length dominant-negative survivin for cancer immunotherapy.
Писарев, В. М., Yu, B., Salup, R. R., Sherman, S., Altieri, D. C., & Gabrilovich, D. I. (2003) · PubMed · Cited by 93
Self-citationThe Immunobiology of Low-Dose Total-Body Irradiation: More Questions than Answers
Safwat, A. (2000) · Radiation Research · doi:10.1667/0033-7587(2000)153[0599:tioldt]2.0.co;2 · Cited by 89
Recent Advances Using Anti-CTLA-4 for the Treatment of Melanoma
Sarnaik, A. A., & Weber, J. S. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181a7450f · Cited by 64
Interferon γ limits the effectiveness of melanoma peptide vaccines
Cho, H.-I., Lee, Y.-R., & Celis, E. (2010) · Blood · doi:10.1182/blood-2010-08-298117 · Cited by 61
Self-citationIncreased protein nitrosylation in head and neck squamous cell carcinogenesis
Bentz, B. G., Haines, G. K., & Radosevich, J. A. (2000) · Head & Neck · doi:10.1002/(sici)1097-0347(200001)22:1<64::aid-hed10>3.0.co;2-j · Cited by 58
Hardy, L., Wick, D. A., & Webb, J. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.5956 · Cited by 56
Recent advances and hurdles in melanoma immunotherapy
Jandus, C., Speiser, D. E., & Romero, P. J. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00634.x · Cited by 48
A Single Peptide–MHC Complex Positively Selects a Diverse and Specific CD8 T Cell Repertoire
Wang, B., Primeau, T. M., Myers, N. B., Rohrs, H. W., Gross, M. L., Lybarger, L. P., Hansen, T. H., & Connolly, J. M. (2009) · Science · doi:10.1126/science.1177627 · Cited by 48
Rotondo, R., Mastracci, L., Piazza, T., Barisione, G., Fabbi, M., Cassanello, M., Costa, R., Morandi, B., Astigiano, S., Cesario, A., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23437 · Cited by 45
Targeting inhibitory pathways in cancer immunotherapy
Lasaro, M. O., & Ertl, H. C. J. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.04.005 · Cited by 28
Expression of the inducible isoform of nitric oxide synthase in pigment cell lesions of the skin
Ahmed, B., & van den Oord, J. J. (2000) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2000.03352.x · Cited by 27
Ultrastructural and Chromosomal Studies on Manganese Superoxide Dismutase in Malignant Mesothelioma
Kinnula, V. L., Torkkeli, T. K., Kristo, P., Sormunen, R. T., Soini, Y., Pääkkö, P. K., Ollikainen, T., Kahlos, K., Hirvonen, A., & Knuutila, S. (2004) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2003-0409oc · Cited by 26
Tumor-Induced Immune Suppression
Gabrilovich, D. I., & Hurwitz, A. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-69118-3 · Cited by 22
Self-citation
Cited by
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Self-citationRecommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Self-citationHayes, J. D., Dinkova-Kostova, A. T., & Tew, K. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.001 · Cited by 2,654
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528
Metadata
- Authors
- Lu, T., Ramakrishnan, R., Altiok, S., Youn, J.-I., Cheng, P., Celis, E., Pisarev, V., Sherman, S., Sporn, M. B., & Gabrilovich, D.
- Venue
- Journal of Clinical Investigation
- Published
- 2011-10-03
- Volume
- 121
- Issue
- 10
- Pages
- 4015-4029
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2136798443
- Cited by
- 367
- References
- 53
- FWCI
- 11.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.